Isavuconazole–tacrolimus drug–drug interactions in HSCT patients
Journal of Antimicrobial Chemotherapy · 03.10.2023 · 78 (10) · 2559-2562
DOI: 10.1093/jac/dkad271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 05.09.2023. Verfasst von L Fructuoso-González und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Pharmacy Service, Hospital Morales Meseguer, Murcia, Spain. Hauptthemen laut MEDLINE: Tacrolimus, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Objectives
Because tacrolimus has a narrow therapeutic window and exhibits both intraindividual and interindividual variability, we attempted to establish the percentage of calcineurin inhibitor (CNI) dose reduction to prevent toxicity and ensure stem cell engraftment when using this immunosuppressant with the antifungal isavuconazole (ISA). By calculating the tacrolimus concentration/dose (C/D) ratio, we expected to demonstrate the magnitude of change in the C/D ratio from baseline after ISA administration.
Methods
We evaluated the interaction between ISA, a new triazole antifungal used in prophylaxis for invasive fungal infections, and the CNI class of immunosuppressive drugs, specifically tacrolimus, in 11 blood samples from HSCT recipients.
Results
The mean tacrolimus C/D ratio increased 1.44-fold from baseline 48 h after ISA administration (P = 0.001).
Conclusions
Although further investigation is needed, the results of this study suggest that a reduction of 18% in tacrolimus may be recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Pharmacy Service, Hospital Morales Meseguer, Murcia, Spain.
- Haematology Service, Hospital Morales Meseguer, Murcia, Spain.
ORCID-Profile: L Fructuoso-González
Zitieren
APA
Fructuoso-González, L., Najera-Perez, M. D., Manresa-Ramón, N., Torrano-Belmonte, P., Caracena-López, S., & Pacheco-López, P. (2023). Isavuconazole–tacrolimus drug–drug interactions in HSCT patients. Journal of Antimicrobial Chemotherapy, 78(10), 2559-2562. https://doi.org/10.1093/jac/dkad271
Vancouver
Fructuoso-González L, Najera-Perez MD, Manresa-Ramón N, Torrano-Belmonte P, Caracena-López S, Pacheco-López P. Isavuconazole–tacrolimus drug–drug interactions in HSCT patients. Journal of Antimicrobial Chemotherapy. 2023;78(10):2559-2562. doi:10.1093/jac/dkad271
BibTeX
@article{FructuosoGonzlez2023,
author = {Fructuoso-González, L and Najera-Perez, M D and Manresa-Ramón, N and Torrano-Belmonte, P and Caracena-López, S and Pacheco-López, P},
title = {Isavuconazole–tacrolimus drug–drug interactions in HSCT patients},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
volume = {78},
number = {10},
pages = {2559--2562},
doi = {10.1093/jac/dkad271}
}
EUVIMED